Logo

Icoria to ID Biomarkers for Isis Pharmaceuticals

Aug 24, 2005

NEW YORK, Aug. 24 (GenomeWeb News) - Icoria will identify biomarkers of toxicity in animal models for Isis Pharmaceuticals, the biotechnology company said yesterday.

Icoria will use its metabolomics platform to evaluate differences in treated and untreated animal subjects to identify biomarkers that Isis will use to suggest pathways for alteration by potential drug candidates, Icoria said.

Financial details were not disclosed.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.